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ABSTRACT
Objective: To determine whether the heterogeneous
clinical response to tumour necrosis factor (TNF)a
blocking therapy in rheumatoid arthritis (RA) can be
predicted by TNFa expression in the synovium before
initiation of treatment.
Methods: Prior to initiation of infliximab treatment,
arthroscopic synovial tissue biopsies were obtained from
143 patients with active RA. At week 16, clinical
response was evaluated using the 28-joint Disease
Activity Score (DAS28). Immunohistochemistry was used
to analyse the cell infiltrate as well as the expression of
various cytokines, adhesion molecules and growth
factors. Stained sections were evaluated by digital image
analysis. Student t tests were used to compare
responders (decrease in DAS28 >1.2) with non-
responders (decrease in DAS28 ,1.2) and multivariable
regression was used to identify the independent
predictors of clinical response.
Results: Synovial tissue analysis confirmed our hypoth-
esis that the baseline level of TNFa expression is a
significant predictor of response to TNFa blocking
therapy. TNFa expression in the intimal lining layer and
synovial sublining were significantly higher in responders
than in non-responders (p=0.047 and p=0.008,
respectively). The numbers of macrophages, macrophage
subsets and T cells (all able to produce TNFa) were also
significantly higher in responders than in non-responders.
The expression of interleukin (IL)1b, IL6, IL18, IL10,
E-selectin, intercellular adhesion molecule (ICAM)-1,
vascular cell adhesion molecule (VCAM)-1, vascular
endothelial growth factor (VEGF) and basic fibroblast
growth factor (bFGF) was not associated with response to
anti-TNFa treatment.
Conclusion: The effects of TNFa blockade are in part
dependent on synovial TNFa expression and infiltration by
TNFa producing inflammatory cells. Clinical response
cannot be predicted completely, indicating involvement of
other as yet unknown mechanisms.
Tumour necrosis factor a (TNFa) blocking agents
as treatment for rheumatoid arthritis (RA) were
developed based on evidence that the pro-inflam-
matory cytokine TNFa plays an important role in
the pathogenesis.
1 Some patients however do not
clinically respond to TNFa blockade. At present no
factors have been identified that fully explain or
predict the differential response.
One explanation for the heterogeneous clinical
response may be found in the baseline variability in
TNFa expression among individual patients.
23
Genetic studies have suggested that individuals
predisposed to high TNF production could show
worse responses to anti-TNFa therapy.
45 By
contrast, a recent study using an in vitro bioassay
suggested that good responsiveness to anti-TNF
therapy is associated with significantly higher
TNFa bioactivity at baseline compared to non-
responding patients.
6 Taken together, it remains to
be determined which baseline cytokine profile
distinguishes responding from non-responding
patients in vivo. Another explanation for the
diversity in response may be that inflammatory
mediators other than TNFa drive different patho-
genetic subsets of RA.
We hypothesised that the pretreatment TNFa
level in the synovium might be related to clinical
efficacy, where TNFa blocking therapy could be
most effective in patients with high pretreatment
TNFa levels, as previously suggested in a small
pilot study.
7 In a prospective study we obtained
arthroscopic synovial tissue samples from 143
patients with RA prior to initiation of infliximab
therapy. We examined the cell infiltrate as well as
the expression of cytokines, adhesion molecules
and growth factors to identify predictors of
clinical response.
PATIENTS AND METHODS
Patients
Consecutive patients with RA according to the
American College of Rheumatology (ACR) criteria
were enrolled in the study. All failed at least two
disease-modifying antirheumatic drugs (DMARDs)
including methotrexate (MTX) and had a 28-joint
Disease Activity Score (DAS28) of >3.2 when
included in the study. Patients were on stable
maximal tolerable MTX treatment (5–30 mg/
week). Oral corticosteroids ((10 mg/day) and
non-steroidal anti-inflammatory drug (NSAIDs)
were allowed if stable for at least 1 month prior
to baseline. Concomitant medication was kept
stable throughout the study. Previous use of a TNF
blocking agent was an exclusion criterion. The
Medical Ethics Committee of the Academic
Medical Center, University of Amsterdam
approved the protocol. All patients gave written
informed consent.
Treatment and evaluation of clinical response
All patients were treated with infliximab according
to the label for RA in a dosage of 3 mg/kg
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every 8 weeks. The DAS28 was evaluated at baseline and weeks
4, 8, 12 and 16 by specially trained research nurses.
For the analysis the absolute change in DAS28 (DDAS28) at
week 16 was dichotomised and defined as non-response
(DDAS28 ,1.2) vs response (DDAS28 >1.2). The dichotomy
of the DDAS28 (on average comparable with a 20% improve-
ment in DAS28) was chosen because it is applied in daily
clinical practice and required for prolongation of reimburse-
ment for TNFa blocking therapy by insurance companies in
The Netherlands. Response was evaluated at 16 weeks
because a significant improvement is expected to occur within
3 to 4 months, after which alternative treatment should be
considered.
8
Arthroscopy and synovial biopsy
Before the first infliximab infusion patients underwent a mini-
arthroscopy under local anaesthesia to obtain synovial tissue
samples from an actively inflamed knee, ankle, wrist or
metacarpophalangeal joint.
9 Biopsies were taken with 2 mm
forceps (Storz, Tuttlingen, Germany) from six or more sites
within the joint to minimise sampling error. Biopsies were
immediately snap frozen en bloc in Tissue Tek OCT (Miles,
Elkhart, Indiana, USA) after collection. Sections of 5 mm were
cut in a cryostat and mounted on Star Frost adhesive glass slides
(Knittelgla ¨ser, Braunschweig, Germany). Slides were stored at
280uC until immunohistochemical staining.
Immunohistochemical analysis
Synovial sections were stained using the following monoclonal
antibodies to analyse the infiltrate: anti-CD55 (67:Serotec,
Oxford, UK) to detect fibroblast-like synoviocytes (FLS), anti-
CD68 (EBM11: DAKO, Glostrup, Denmark) to detect macro-
phages, anti-CD3 (SK7, Becton Dickinson (BD), California,
USA) for T cells, anti-CD22 (CLB-B-ly/1,6B11, The
Netherlands) for B cells and anti-CD38 (HB7, BD) for plasma
cells. CD163 (Ber-MAC3; DAKO) was stained to detect resident
tissue macrophages; infiltrating macrophages were evaluated by
detection of myeloid related protein (MRP)8 (8-5c2, BMA
Biomedicals, Augst, Switzerland) and MRP14 (S36.48, BMA
Biomedicals). For the detection of cytokines, adhesion molecules
and growth factors we used anti-human TNFa (52B83;
Monosan, Brussels, Belgium), anti-interleukin (IL)6
(Nephrology Department, Leiden University Medical Center,
Leiden, The Netherlands), anti-IL10 (23738.111, R&D,
Abingdon, UK), anti-IL18 (2d3b6, MD Biosciences, Minnesota,
USA), anti-IL1b (2D8, ImmunoKontact, Oxford, UK), anti-
intercellular adhesion molecule (ICAM)-1 (MEM111, Sanbio,
Erembodegem, Belgium), anti-vascular cell adhesion molecule
(VCAM) (1G11B1, Sanbio), anti-E-selectin (BBIG-E4, R&D),
anti- vascular endothelial growth factor (VEGF) (N.010313 C-1,
Santa Cruz, California, USA) and anti-basic fibroblast growth
factor (bFGF) (F14220, BD). Staining of cellular markers was
performed using a three-step immunoperoxidase method.
2 For
staining of cytokines, adhesion molecules and growth factors,
biotinylated tyramine was used as amplification. For control
sections the primary antibody was omitted or irrelevant
immunoglobulins were applied.
Digital image analysis
All sections were analysed at random by trained analysts
blinded for clinical outcome. Images were acquired and analysed
by computer-assisted image analysis using a Syndia algorithm
on a Qwin-based analysis system (Leica, Cambridge, UK).
10 A
total of 18 high-power fields per marker were analysed. Cellular
markers were expressed as positive cells/mm
2 (counts/mm
2).
Staining of cytokines, adhesion molecules and growth factors
was expressed as integrated optical density/mm
2 (IOD/mm
2).
CD68+ macrophages and TNFa expression were analysed
separately in the intimal lining layer and the sublining.
Statistical analysis
Independent Student t tests or Mann–Whitney U tests were
used to detect significant differences in baseline parameters
between responders and non-responders. The x
2 test was
employed to compare the percentage of erosive, IgM-rheuma-
toid factor (RF) and anti-cyclic citrullinated peptide (CCP)
positive patients in the responder and non-responder groups.
Variables with a p value ,0.1 in the univariable analysis were
selected as possible predictors in a stepwise backward multi-
variable logistic regression model. Several exchangeable predic-
tion sets were constructed based on the correlation structure
among the potential predictors with strongly correlating
predictors in different sets. The model with the highest
explained variance according to Nagelkerke is reported.
Correlations were assessed with the Pearson product-moment
or Spearman rank-order correlation coefficients, whichever was
appropriate. SPSS V.11.1.4 (Chicago, Illinois, USA) was used.
Because the primary objective of this study was to find a
pathogenetic mechanism in synovial tissue relating to clinical
response, a per-protocol analysis was performed.
RESULTS
Enrolment, discontinuation and exclusion
A total of 143 patients were enrolled. The population was
predominantly female (74%), RF positive (71%) with a mean
(SD) age of 55 (13) years and mean disease duration of 125
(108) months. Erosions were present in 110 (77%) patients. The
mean DAS28 score was 5.9 (1.0) at baseline and the mean MTX
dose was 18.2 (8.5) mg/week. In three patients, a flare of
arthritis at week 6 (n=1) and week 12 (n=2) was the reason
for discontinuation. These patients were analysed as non-
responders. Patients (n=18) who violated the protocol or
discontinued infliximab therapy (for reasons other than non-
response) were excluded.
Synovial tissue exclusion
Following strict quality control, 23 synovial biopsies were
excluded by a blinded assessor for absence of an intimal lining
layer. After excluding 18 patients from the response analysis
and 23 synovial biopsies from the tissue analysis a total of 103
completely evaluable patients remained for the analysis of
synovial tissue in combination with clinical response.
Baseline patient characteristics
The remaining group of 103 patients who were analysed for
response in combination with synovial tissue consisted of 71
females and 32 males, of whom 75% were rheumatoid factor
positive. The mean (SD) age was 55 (13) years and the mean
disease duration was 125 (110) months. Erosions were present
in 79 (77%) patients. The mean DAS28 score was 5.9 (1.1) at
baseline and the mean MTX dose was 18.8 (8.5) mg/week.
Corticosteroids were used by 28 (27%) patients with a mean
dose of 8.0 (2.9) mg/day. On average, patients had failed
treatment with 2.2 DMARDs before inclusion in the study. No
notable changes occurred in the baseline characteristics of the
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of all 143 enrolled patients (see table 1).
Clinical response
Of 103 patients, 70 (68%) were DAS28 responders and 33 (32%)
non-responders at week 16. The clinical efficacy matched the
expected 60–70% responders observed in previous randomised
controlled trials with infliximab in patients with RA. The mean
change in DAS28 was 1.84 (1.26) at week 16. For non-
responders the average DDAS28 was 0.45 (0.58) compared to
2.52 (0.89) for responders. This difference was highly significant
(p,0.001).
All baseline patient characteristics were also tested for
differences between responders and non-responders. The
DAS28 at baseline was nearly significant and was included in
the prediction model (p=0.07). The same holds for anti-CCP
positivity (p=0.08). Finally, there were significantly more
rheumatoid factor positive patients in the responder compared
to the non-responder group (p=0.020), (see table 1).
Baseline synovial TNFa expression and the number of major
TNFa producing cells are associated with clinical response
(DDAS28 >1.2) after 16 weeks of TNFa blocking therapy
Scatter diagrams of the synovial predictors in individual patients
in both response groups are presented in fig 1. TNFa expression
levels were higher in the synovial sublining of responders
compared to non-responders (p=0.008) (fig 1A). Similarly,
TNFa expression in the intimal lining layer was higher in
responders compared to non-responders (p=0.047). Table 2
shows the associations of synovial markers and response.
Because macrophages are known to be the main TNFa
producing cells in the synovium, the number of macrophages
was studied. The mean number of CD68+ sublining macro-
phages was significantly higher in responders than in non-
responders (p=0.029) (fig 1C). Similarly, the number of
CD163+ resident tissue macrophages as well as the number of
infiltrating MRP8+ and MRP14+ macrophages was higher in
responders (p=0.017, p=0.018 and p=0.024, respectively)
(fig 1D). Finally, the median number of CD3+ T cells was higher
in responders (p=0.001) (fig 1B).
Baseline TNFa is the only significant synovial predictor of
response
The relationship between TNFa expression and clinical response
was confirmed by stepwise backward multivariable logistic
regression analysis. Due to multicolinearity among predictors,
10 exchangeable bivariate prediction sets were constructed
consisting of (1) TNFa expression in either the intimal lining
layer or synovial sublining with (2) one out of five cellular
markers. This revealed that TNFa expression in the synovial
sublining was the only independent, early determinant of
therapy response (p=0.011), explaining just about 10% of the
variance in response to therapy (R
2=0.099, according to
Nagelkerke, odds ratio (OR)=1.013). Likewise, TNFa expres-
sion in the intimal lining layer rather than synovial sublining
explained 9% of the variance in response to therapy (p=0.020),
(R
2=0.089, OR=1.017). Thus, after adjustment for TNFa in a
bivariate logistic regression model including either the numbers
of CD68+ sublining macrophages, CD163+, MPR8+, MRP14+
macrophages, or CD3+ T cells, these cellular markers were no
longer significantly associated with response. The removal of
these cellular markers from the model is consistent with the
notion that these cells are the main producers of TNFa.
Contribution of disease activity at baseline to the prediction of
response
To assess the value of a combined prediction model consisting of
clinical and synovial data we added the relevant clinical
variables (DAS28 score, the presence of IgM-RF or anti-CCP
antibodies) to the 10 bivariate synovial models. With stepwise
backward multivariate logistic regression this resulted in a
significant prediction model with TNFa expression in the
Table 1 Baseline patient characteristics
Analysed patients
(n=103) Responders (n=70)
Non-responders
(n=33) p Value
Demographics:
Age (years) 55 (13) 54 (13) 56 (12) 0.40
Female (%) 71 (69) 51 (73) 20 (61) 0.21
Disease status:
Disease duration
(months)
125 (110) 123 (111) 130 (110) 0.80
Erosive disease (%) 79 (77) 57 (81) 22 (67) 0.10
RF positive (%) 77 (75) 57 (81) 20 (61) 0.02
Anti-CCP positive (%) 78 (76) 57 (81) 13 (39) 0.08
DAS28 5.9 (1.1) 6.0 (1.0) 5.6 (1.2) 0.07
Patients global score
(0–100 mm)
60 (22) 62 (21) 56 (23) 0.23
ESR (mm/h) 34 (24) 36 (23) 29 (25) 0.16
CRP (mg/dl) 22 (28) 24 (26) 19 (30) 0.36
Drug treatments:
Previous DMARDs 2.2 (1.5) 2.1 (1.4) 2.4 (1.6) 0.42
Methotrexate (mg/
week)
18.8 (8.5) 19.5 (8.2) 17.1 (8.9) 0.18
Receiving
corticosteroids (%)
28 (27) 22 (31) 6 (18) 0.22
Receiving NSAIDs (%) 52 (50) 35 (50) 17 (52) 0.89
Mean (SD), median and interquartile range (IQR) or percentages are shown. p Values ,0.05 (two-sided) were considered
significant.
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying
antirheumatic drug; ESR, erythrocyte sedimentation rate; NSAID, non-steroidal anti-inflammatory drug; RF, rheumatoid factor.
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(p=0.031, OR=1.611) with an increased explained variance
of 17% (R
2=0.172). A similar analysis except with TNFa
expression in the intimal lining layer (p=0.023, OR=1.017)
resulted in a significant model including the DAS28 (p=0.044,
OR=1.588) and the presence of anti-CCP antibodies (p=0.046,
OR=3.038) (R
2=0.182).
Baseline IL1b, IL6, IL18 and IL10 expression is not associated
with response to TNFa blocking therapy
In addition to TNFa we studied the expression of other
cytokines such as IL18, which is believed to operate mainly
upstream of TNFa, while IL1b and IL6 appear to act mainly
downstream of TNFa. Despite the known interplay of these
cytokines with TNFa we found no relationship between
synovial expression levels of either of these cytokines and
clinical response. We did find, however, a significant correlation
between the level of IL1b expression and TNFa expression
(r=0.306, p=0.014). The expression level of IL10 was not
different between response groups (see table 2).
Baseline expression of adhesion molecules and angiogenic
factors is not associated with response to TNFa blocking
therapy
In accordance with their function in leukocyte recruitment a
significant correlation was found between the number of
sublining macrophages on the one hand and the expression of
the vascular adhesion molecules E-selectin (Spearman rho
correlation coefficient 0.275–0.536, p,0.01) on the other.
However, the level at which the adhesion molecules were
expressed in the synovium at baseline did not differ between
responders and non-responders. Furthermore, VEGF is known
to mediate angiogenesis and is regulated by pro-inflammatory
cytokines such as TNFa. However, no association was found
between VEGF expression and response (table 2). Similarly, no
difference was found in the expression of bFGF.
DISCUSSION
The primary objective of this study was to investigate whether
immunohistological assessment of the cell infiltrate and
cytokine expression in the synovium prior to initiation of
Figure 1 A. The median synovial
sublining tumour necrosis factor (TNF)a
expression was higher in responders
compared to non-responders (p=0.008).
B. The median number of CD3+ T cells in
responders vs non-responders
(p=0.001). (C) The mean number of
CD68+ sublining macrophages was also
higher in responders 576 (428), than in
non-responders 387 (338) (p=0.029).
(D) CD163+ macrophages in responders
vs non-responders (p=0.017).
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patients with RA. We could confirm our hypothesis that the
level of synovial TNFa expression is a significant early predictor
of the response. This was shown by increased TNFa expression
levels in the intimal lining layer and synovial sublining of
responding compared to non-responding patients. In line with
these findings, there was increased infiltration by macrophages,
including CD163+ resident tissue macrophages and MRP8+ and
MRP14+ infiltrating macrophages, as well as T cells in
responders vs non-responders. It is important to note that
these cells are the main source of TNFa in the synovium of
patients with RA.
11
Consistent with the clinical experience that the response to
TNFa blockade is not a dichotomous phenomenon,
12 there was
no distinct threshold value in TNFa expression in the synovium
of patients with RA. Multivariate logistic regression analysis of
synovial markers showed that TNFa expression in the sublining
could explain about 10% of the variance in response to therapy.
After adjusting for disease activity at baseline this further
increased to 17%. Hence, the predictive value of synovial TNF
expression is statistically significant, but overall limited. This
clearly indicates that variables other than synovial TNFa
expression are involved as well. The results presented here
show for the first time that the expression of IL1b, IL6, IL18,
IL10, E-selectin, ICAM-1, VCAM-1, VEGF and bFGF is not
associated with clinical response to anti-TNFa treatment. Thus,
the features of synovial inflammation at baseline in responders
to anti-TNF therapy compared to non-responders do not
merely represent a greater amount of inflammation, but the
results presented here underscore the importance of specific
inflammatory pathways. Future work should expand the
search for other biomarkers and molecular networks to better
understand the variable response to anti-TNFa therapy.
The search for predictors of response is important in the
context of personalised medicine, which may be an effective
approach to increase the percentage of patients exhibiting a
robust response to a given treatment. Previous work has clearly
suggested that RA consists of different pathogenetic subsets,
leading to common signs and symptoms associated with what
we at present define clinically as RA.
231 3Thus, it is conceivable
that, for instance, TNFa expression is more important in some
patients than in others, and that TNF blockade could be more
effective in the former. Although we are as yet not able to
predict the response sufficiently to select patients who are likely
to have a beneficial response to a specific treatment before
initiation of therapy and to guide treatment decisions, the
results of the present study do provide proof of principle that
this might be achieved by further optimisation of the
biomarkers or perhaps combinations with other clinical and
biological variables that need to be identified. The relevance of
this approach is underscored by the expanding array of
biological therapies and their costs.
14
There is no evidence that simple measurement of plasma
TNFa levels can be used to predict clinical response to TNFa
blockade. As it appears logical that patients producing high
levels of TNFa at the site of inflammation are more likely to
benefit from TNFa blockade than those with lower TNFa
levels, we focused on the synovium as the primary target of RA.
The association between pretreatment TNFa expression in the
synovium and clinical response to 3 mg/kg of infliximab
described here in 103 patients with RA confirms and extends
a trend observed in a pilot study in patients with RA where
4 out of 8 patients who met the ACR50 response criteria at
2 weeks after initiation of infliximab (10 mg/kg) therapy were
those with the highest levels of TNFa expression in the
synovium, as shown by immunohistochemistry.
7 Of interest,
Table 2 Associations of studied synovial predictors with clinical response
DDAS28 score
p Value Responders (n=70) >1.2 Non-responders (n=33) ,1.2
Cytokines (IOD/mm
2):
TNFa lining 48 214 (29 116–88 971) 36 376 (23 394–54 271) 0.047
TNFa sublining 77 947 (38 710–123 535) 46 033 (19 890–78 129) 0.008
IL1b 56 278 (31 063–81 655) 54 484 (32 098–129 041) 0.814
IL6 50 537 (41 939) 38 364 (28 527) 0.135
IL10 131 106 (87 359) 115 964 (83 953) 0.415
IL18 9530 (12 086) 7009 (7470) 0.289
Cellular markers (counts/mm
2 )
CD55 652 (418) 694 (389) 0.895
CD3 149 (66–385) 47 (22–163) 0.001
CD68 lining 374 (253) 295 (184) 0.130
CD68 sublining 576 (428) 387 (338) 0.029
CD163 1100 (432) 878 (433) 0.017
CD22 54 (99) 47 (111) 0.756
CD38 284 (384) 325 (556) 0.661
MRP8 139 (35–294) 53 (19–135) 0.018
MRP14 159 (34–526) 51 (18–166) 0.024
Adhesion molecules (IOD/mm
2)
ICAM 30 790 (33 016) 22 321 (21 706) 0.195
VCAM 80 065 (52 630) 70 701 (44 574) 0.387
E-Selectin 37 651 (40 134) 30 488 (29 972) 0.373
Growth factors (IOD/mm
2 )
VEGF 18 252 (78 689) 5776 (5372) 0.374
bFGF 209 (736) 64 (163) 0.276
*Data are presented as mean (SD) or median (interquartile range), whichever appropriate. p Values,0.05 (two-sided) were considered significant.
bFGF, basic fibroblast growth factor; ICAM, intercellular adhesion molecule; IF, interferon; IOD, integrated optical density; MRP, myeloid related protein; TNF, tumour necrosis factor;
VCAM, vascular cell adhesion molecule; VEGF, vascular endothelial growth factor.
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suggesting that clinical response at 52 weeks is associated with
significantly higher circulating TNFa bioactivity (measured by
an in vitro bioassay) at baseline in responding compared to non-
responding patients.
6 Together, these studies support the notion
that the initial clinical response to TNFa blockade is related to
pretreatment levels of TNFa production. In patients who
initially respond, but loose response over time, other mechan-
isms such as formation of antibodies against the drug may be
operative.
15
In conclusion, the results presented here show proof of
principle that the heterogeneous response to TNFa blockade is
associated with TNFa expression in the inflamed synovium.
Future work should expand the search for other biomarkers and
molecular networks as well as combinations with clinical
variables. Thus, the prediction of how a patient will respond
might come in reach of the treating doctor.
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